This symposium offered critical, up-to-date information across key neurological areas, providing actionable insights highly relevant to general practice.
The lectures provide essential updates on dementia management, emphasizing that significant cognitive decline is not part of normal aging. You’ll receive crucial details on emerging, disease-modifying Alzheimer’s therapies. This includes strict eligibility criteria (mild cognitive impairment or mild dementia) and the necessity for intensive safety monitoring and high cost (around $77,000+ per course).
Furthermore, the presentations delve into diagnosing and managing migraines, outlining red flag symptoms (the SNOOP acronym) and modern preventative options, including CGRP antagonists and gepants.
For Parkinson’s disease, experts discuss the growing evidence linking the disease to environmental exposures and review advanced therapies. Crucially, there is detailed guidance on complex areas like medico-legal assessments, reinforcing that capacity is decision-specific and a diagnosis of dementia does not automatically mean a person lacks capacity. Finally, practical advice is offered on navigating the difficult NDIS and My Aged Care systems, stressing the importance of early registration and precise documentation of functional needs.
Watching these lectures will enhance your clinical knowledge, ensuring you can offer your patients the earliest possible diagnosis and access to cutting-edge treatments and support systems.